aid: abgenomics
name: Abgenomics
description: 'AbGenomics (AbGenomics International, Inc.) is a clinical-stage biopharmaceutical
  company founded in 2000 with offices in the San Francisco Bay Area, California and an
  R&D center in Taipei, Taiwan. It develops targeted antibody therapeutics for immune-mediated
  inflammatory disease and cancer, built on a PSGL-1 T-cell checkpoint regulator platform,
  with clinical candidates including neihulizumab (AbGn-168H / ALTB-168) and the antibody-drug
  conjugate AbGn-107. The company rebranded as AltruBio, Inc. in 2020 and now operates at
  altrubio.com; the original abgenomics.com domain is a parked for-sale listing. It is a
  therapeutics developer, not a software vendor: it publishes no developer program, no public
  API, no SDKs and no machine-readable API description of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/abgenomics/refs/heads/main/apis.yml
image: https://www.altrubio.com/assets/img/logo.png
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: 'enrichment pass 2026-09-06: full STEP 0b contract discovery run across abgenomics.com and the successor altrubio.com — no OpenAPI, GraphQL, MCP, A2A card, WSDL, proto or well-known document found; clinical-stage biopharma with no developer program'
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Therapeutics
- Clinical Research
- Immunology
- Oncology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/abgenomics-domain-security.yml
- type: Website
  url: https://www.altrubio.com/altrubio/en
- type: PrivacyPolicy
  url: https://www.altrubio.com/altrubio/en/privacy
- type: Support
  url: https://www.altrubio.com/altrubio/en/contact
x-successor:
  name: AltruBio, Inc.
  website: https://www.altrubio.com/altrubio/en
  note: >-
    AbGenomics rebranded as AltruBio, Inc. in 2020 (name change, new leadership, shift from
    oncology to immunology). The Website/PrivacyPolicy/Support pointers resolve to the successor's
    live site because the company's own abgenomics.com domain now serves an abovedomains.com
    "this domain may be for sale" parking page (HTTP 200, 1,005 bytes, ns1/ns2.abovedomains.com).
x-enrichment:
  date: '2026-09-06'
  status: minimal
  artifacts_added: 2
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    AbGenomics is a clinical-stage biopharmaceutical developer of antibody therapeutics (now
    trading as AltruBio) whose product is a drug pipeline, not software — its own abgenomics.com
    domain has been released to an abovedomains.com "this domain may be for sale" parking page,
    and the successor site altrubio.com publishes only pipeline, news and careers pages with no
    developer program, no API, no SDK and no /llms.txt.
  evidence:
    - url: https://abgenomics.com/
      status: 200
    - url: https://abgenomics.com/.well-known/apis.json
      status: 404
    - url: https://www.altrubio.com/altrubio/en
      status: 200
    - url: https://www.altrubio.com/llms.txt
      status: 200
    - url: https://api.github.com/orgs/abgenomics
      status: 404
  checked: '2026-09-06'